Ezetimibe safety

Abstract The ATP binding cassette transporters ABCG5 G5 ; and ABCG8 G8 ; limit the accumulation of neutral sterols by restricting sterol uptake from the intestine and promoting sterol excretion into bile. Humans and mice lacking G5 and G8 G5G8 ; accumulate plant sterols in the blood and tissues. However, despite impaired biliary cholesterol secretion, plasma and liver cholesterol levels are lower in G5G8 mice than in wild-type littermates. To determine whether the observed changes in hepatic sterol metabolism were a direct result of decreased biliary sterol secretion or a metabolic consequence of the accumulation of dietary noncholesterol sterols, we treated G5G8 mice with ezetimibe, a drug that reduces the absorption of both plant- and animal-derived sterols. Ezetimibe feeding for 1 month sharply decreased sterol absorption and plasma levels of sitosterol and campesterol but increased cholesterol in both the plasma from 60.4 to 75.2 mg dl ; and the liver from 1.1 to 1.87 mg g ; of the ezetimibe-treated G5G8 mice. Paradoxically, the increase in hepatic cholesterol was associated with an increase in mRNA levels of HMG-CoA reductase and synthase. Together, these results indicate that pharmacological blockade of sterol absorption can ameliorate the deleterious metabolic effects of plant sterols even in the absence of G5 and G8.--Yu, L., K. von Bergmann, D. Ltjohann, H. H. Hobbs, and J. C. Cohen. Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8. J. Lipid Res. 2005. 46: 17391744. View boards, and all patients provided written informed consent before initiation of any study procedure. Patients discontinued fibrate therapy 9 weeks before and all other lipid-lowering therapies 7 weeks before the start of the study. After the placebo diet run-in period, eligible patients were randomized to 1 of treatment groups in a 1: allocation. Force titration occurred over a four 6-week treatment periods as follows for each of the 3 treatment groups: 1 ; 10 mg of atorvastatin as the initial dose was titrated to 20, 40, and 80 mg; 2 ; co-administration of 10 mg of ezetimibe simvastatin was titrated to 10 20, 10 and 10 80 mg; and 3 ; coadministration of 10 20 mg of ezetimibe simvastatin was titrated to 10 40 mg for 2 treatment periods ; and to 10 80 mg in the last treatment period Table 1 ; . To decrease the number of daily tablets, a partial-blinding scheme was used. Patients took 4 tablets 1 active and 3 placebo ; each evening during the placebo run-in phase and periods 1 and 2 and 3 tablets 1 active and 2 placebo ; during periods 3 and 4. The mix of placebo tablets was changed to maintain the blind. Randomization was centrally stratified by baseline LDL cholesterol level 130 and 160 mg dl, 160 and 190 mg dl, and 190 mg dl ; to provide balance across treatment groups. Study population: Patients 18 years with a LDL cholesterol level at or above drug treatment threshold established by National Cholesterol Education Pro0002-9149 04 $see front matter doi: 10.1016 j.amjcard.2004.02.060.

Table 2 Baseline values mean ; and least-square mean percentage changes SEM ; in plasma concentrations of various lipidrelated variables from baseline to endpoint for all randomized patients Variable Placebo n 204 ; a Baseline Direct LDL-C Calculated LDL-C Apolipoprotein B HDL-C HDL2-C HDL3-C Apolipoprotein A-I TC Direct LDL-C: HDL-C TC: HDL-C Triglycerides Lipoprotein a ; 4.25 mmol l 4.23 mmol l 1.61 g l 1.32 mmol l 0.52 mmol l 0.80 mmol l 1.51 g l 6.43 mmol l 3.38 5.10 1.93 mmol l 336 mg l % Change 0.79 1.36 -1.01 -1.26 -1.14 3.94 1.20 0.57 ; 0.79 ; 0.81 ; 0.78 ; 2.34 ; 1.53 ; 0.88 ; 0.60 ; 1.00 ; 0.82 ; 2.24 ; 2.88 ; Ezetimibe 10 mg n 621 ; a Baseline 4.27 mmol l 4.0 mmol l 1.62 g l 1.35 mmol l 0.53 mmol l 0.83 mmol l 1.53 g l 6.44 mmol l 3.36 5.04 1.84 mmol l 308 mg l % Change -17.69 -18.24 -15.38 1.01 5.03 2.84 -12.40 -18.25 -12.78 -1.71 -7.50 0.59 ; 0.51 ; 0.52 ; 0.50 ; 1.61 ; 1.05 ; 0.57 ; 0.38 ; 0.68 ; 0.52 ; 1.43 ; 1.86 ; 0.01 P value.

Ezetimibe tablet